$10,000 Invested in Eli Lilly 5 Years Ago Would Be Worth This Much Today
Key Points
Eli Lilly has crushed broader equities over the past five years.
The company has what it takes to continue performing well over the medium term.
- 10 stocks we like better than Eli Lilly ›
Eli Lilly (NYSE: LLY) has achieved several impressive milestones over the past five years, including becoming the first healthcare company to reach a $1 trillion market cap. And over this period, the stock has delivered outstanding returns.
Image source: The Motley Fool.
Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
To illustrate just how impressive Eli Lilly's performance has been, consider that if you had invested $10,000 in the stock five years ago, you'd have about $54,477 today, given the company's 40.36% average annual return over this period (the amount includes dividend reinvestment). By contrast, if you had put that $10,000 into an ETF that perfectly matches the returns of the S&P 500, you'd have $17,940 today. That's not bad at all. But the index's returns over the past five years pale in comparison to Eli Lilly's. Of course, investors want to know whether the pharmaceutical giant can keep going. There are good reasons why the answer to that question is a resounding yes.
Eli Lilly is one of the leaders in the rapidly growing GLP-1 market. The company's most important medicines are recording outstanding sales growth, and it boasts a deep pipeline -- that is arguably second to none -- in its core therapeutic area. Further, Eli Lilly has a vast pipeline in other areas and could make significant progress over the next few years, resulting in a much more diversified lineup of approved drugs. Even with mounting competition in the GLP-1 industry, Eli Lilly's prospects look attractive. I wouldn't expect the stock to deliver average annual returns of about 40% through 2031, but the healthcare leader still seems well positioned to beat the broader equity market.
Should you buy stock in Eli Lilly right now?
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $344,608!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,327,222!*
Now, it’s worth noting Stock Advisor’s total average return is 904% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of October 27, 2026.
Prosper Junior Bakiny has positions in Eli Lilly. The Motley Fool has positions in and recommends Eli Lilly. The Motley Fool has a disclosure policy.
Recommended Articles
